Holen Sie sich die Stockscreener-App
29.27
0.83%
0.24
Handel nachbörslich:
28.96
-0.31
-1.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
Reports Suggest TG Therapeutics May Be Scaling Back Operations Amid Speculation on CafePharma Forum - geneonline.com
TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright - MarketBeat
TG Therapeutics Azer Cel Milestone Adds Depth To Autoimmune Valuation Story - simplywall.st
TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright - MarketBeat
TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth - The Globe and Mail
Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus
TG Therapeutics, Inc. (TGTX) Growth Potential: Navigating A 47.65% Upside In Biotech - DirectorsTalk Interviews
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire
Is TG Therapeutics’ 2025 Earnings Miss and BRIUMVI Guidance Shift Altering The Investment Case For TGTX? - Sahm
HC Wainwright Raises Earnings Estimates for TG Therapeutics - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 Earnings Call Transcript - Insider Monkey
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 - Finviz
TG Therapeutics (TGTX) Earnings Spark Debate As 72.6% Net Margin Defies Forecast Narratives - Sahm
TG Therapeutics Five Year Briumvi Data Highlights Durable Efficacy And Valuation Gap - Sahm
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line - The Globe and Mail
Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus
TGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
TG THERAPEUTICS, INC. SEC 10-K Report - TradingView
TG Therapeutics: "Strong Buy" On BRIUMVI's Massive Growth And Possible Expansion (TGTX) - Seeking Alpha
(TGTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
TG Therapeutics Experiences Evaluation Revision Amidst Evolving Market Dynamics - Markets Mojo
TG Therapeutics Q4 Earnings Call Highlights - MarketBeat
Q1 EPS Estimates for TG Therapeutics Raised by HC Wainwright - MarketBeat
Analysts’ Top Healthcare Picks: United Therapeutics (UTHR), TG Therapeutics (TGTX) - The Globe and Mail
TG Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript - The Globe and Mail
Earnings call transcript: TG Therapeutics Q4 2025 earnings miss EPS expectations - Investing.com
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates - Yahoo! Finance Canada
TG Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TG Therapeutics: Fourth Quarter Financial Highlights - Bitget
TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook - ChartMill
TG Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
TG Therapeutics (TGTX) Reports Q4 Earnings Miss - GuruFocus
TG Therapeutics Q4 Earnings Fall, Revenue Rises; Issues 2026 Revenue Guidance; Shares Down Pre-bell - marketscreener.com
Earnings Flash (TGTX) TG Therapeutics Posts Q4 EPS $0.14, vs. FactSet Est of $0.35 - marketscreener.com
TGTX Projects Strong Financial Performance Through 2026 - GuruFocus
TGTX Financial Health and Future Funding Outlook - GuruFocus
TG THERAPEUTICS ($TGTX) Releases Q4 2025 Earnings - Quiver Quantitative
TG Therapeutics Q4 revenue rises on BRIUMVI sales, but profit dips - TradingView
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
TG Therapeutics Q4 Earnings Assessment - Benzinga
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance - Yahoo Finance
TG Therapeutics, Inc. $TGTX Stock Holdings Increased by Citigroup Inc. - MarketBeat
Five-Year BRIUMVI Data Shapes TG Therapeutics Multiple Sclerosis Investment Case - Sahm
Does TG Therapeutics (TGTX) Offer Value After Recent Share Price Swings - simplywall.st
A Look at TG Therapeutics's Upcoming Earnings Report - Benzinga
TG Therapeutics faces earnings test as Briumvi growth accelerates - Investing.com India
TG Therapeutics (TGTX) Set to Announce Q4 Earnings with Positive Revisions - GuruFocus
Vanguard Group Inc. Lowers Stock Position in TG Therapeutics, Inc. $TGTX - MarketBeat
FOMO Trade: Is TG Therapeutics Inc a top pick in the sectorWeekly Stock Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Goldman Sachs raises TG Therapeutics, Inc. (TGTX) target to $39 on 2026 guidance - MSN
Aug Rallies: Is TG Therapeutics Inc undervalued by DCF analysisWeekly Investment Report & Expert Curated Trade Setup Alerts - baoquankhu1.vn
TG Therapeutics, Inc. (TGTX) Stock Analysis: A 50% Upside Potential In Biotech - DirectorsTalk Interviews
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Finviz
TG Therapeutics to Host Conference Call Discussing Q4 and Full Year 2025 Financial Results and 2026 Outlook - Quiver Quantitative
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update - marketscreener.com
TG Therapeutics (TGTX) to Release Earnings on Monday - MarketBeat
1.24%
2.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):